Hepatitis B Reactivation and Rituximab in the Oncology Practice
- 1 October 2010
- journal article
- review article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 15 (10) , 1113-1121
Abstract
Rituximab use in hematology and oncology practice has significantly and positively improved the clinical outcomes in patients with a wide variety of B-cell lymphoproliferative disorders. However, emerging data reveal that there is a risk of viral hepatitis B reactivation in some patients treated with rituximab. Many of these cases result in treatment delays, inferior oncologic outcomes, increased morbidity, and more rarely fulminant hepatic decompensation and death. Indeed, the rituximab package insert and many clinical practice guidelines have been modified to reflect these concerns. The true incidence and mechanism of reactivation are still being elucidated. This article focuses on the current evidence that supports these recently revised clinical recommendations along with a review of the risk factors for reactivation, suggested monitoring, and preventative interventions.Keywords
This publication has 58 references indexed in Scilit:
- Chronic hepatitis B: Update 2009 #Hepatology, 2009
- Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenanceHaematologica, 2009
- Hepatitis B Virus Reactivation in Lymphoma Patients With Prior Resolved Hepatitis B Undergoing Anticancer Therapy With or Without RituximabJournal of Clinical Oncology, 2009
- Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patientsBreast Cancer Research and Treatment, 2004
- Once-Daily versus Twice-Daily Lamivudine, in Combination with Zidovudine and Efavirenz, for the Treatment of Antiretroviral-Naive Adults with HIV Infection: A Randomized Equivalence TrialClinical Infectious Diseases, 2004
- Preemptive use of lamivudine in breast cancer patients carrying hepatitis B virus undergoing cytotoxic chemotherapy: a longitudinal follow-upSupportive Care in Cancer, 2004
- Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonrespondersJournal of Hepatology, 2003
- Lamivudine allows completion of chemotherapy in lymphoma patients with hepatitis B reactivationBritish Journal of Haematology, 2000
- Lamivudine as Initial Treatment for Chronic Hepatitis B in the United StatesNew England Journal of Medicine, 1999
- A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infectionThe Journal of Pediatrics, 1998